iota Biosciences is differentiated by its ultrasonic powering architecture for sub-millimeter implants, a technically compelling approach that eliminates batteries and reduces implant size to needle-injectable dimensions. As an Astellas acquisition, it is best understood as pharma-enabling bioelectronic infrastructure rather than an independent device company pursuing its own commercial pathway.